Publications by authors named "Jan Lier"

Claim this Profile
F
First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor.
Hidetoshi Shimizu, Michael A Tortorici, Yoshiyasu Ohta, Kei Ogawa, Sheikh Mohammed Ashfaq Rahman, Jan Jaap van Lier

Clin Transl Sci· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, Distribution, Metabolism, and Excretion of [C]iptacopan in Healthy Male Volunteers and in In Vivo and In Vitro Studies.
Alexander David James, Kenneth Kulmatycki, Birk Poller, Andrea A Romeo, Jan Jaap Van Lier

Drug Metab Dispos· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictability of Elimination and Excretion of Small Molecules in Animals and Humans, and its Impact on Dosimetry for human ADME Studies with Radiolabeled Drugs.
Ad Roffel, Jan Jaap van Lier, Gerk Rozema, Ewoud-Jan van Hoogdalem

Curr Rev Clin Exp Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
Holger Scheible, Martin Dyroff, Annick Seithel-Keuth, Eleanor Harrison-Moench, Nadra Mammasse, Jan Jaap van Lier

Clin Transl Sci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and - Preliminary Dynamics of Neuroprotectant 2-Iminobiotin in Healthy Subjects.
Ewoud-Jan van Hoogdalem, Cacha M P C D Peeters-Scholte, Paul W T J Leufkens, Jan Hartstra, Jan J van Lier

Curr Clin Pharmacol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
Andreas Johne, Holger Scheible, Andreas Becker, Jan Jaap van Lier, Peter Wolna

Invest New Drugs· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P receptor modulator in healthy subjects.
Marie-Laure Boof, Jan Jaap van Lier, Stephen English, Hartmut Fischer, Mike Ufer

Xenobiotica· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects.
Mike Ufer, Christine Huynh, Jan Jaap van Lier, Eva Caroff, Hartmut Fischer

Xenobiotica· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.
Frank Richard, Jan Jaap van Lier, Bernard Roubert, Teba Haboubi, Udo-Michael Göhring

Am J Hematol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species.
Lene Jensen, Hans Helleberg, Ad Roffel, Jan Jaap van Lier, Inga Bjørnsdottir

Eur J Pharm Sci· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.
Andreas Becker, Oliver von Richter, Andreas Kovar, Holger Scheible, Jan J van Lier

J Clin Pharmacol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
Armel Stockis, Jan Jaap van Lier, Willi Cawello, Thomas Kumke, Klaus Eckhardt

Epilepsia· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Shin Takusagawa, Jan Jaap van Lier, Katsuhiro Suzuki, Masanori Nagata, John Meijer

Drug Metab Dispos· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.
Monika Malm-Erjefält, Inga Bjørnsdottir, Jan Vanggaard, Hans Helleberg, Uffe Larsen, Jan Jaap van Lier

Drug Metab Dispos· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
Joep de Bruijne, Jilling F Bergmann, Henk W Reesink, Christine J Weegink, Richard Molenkamp, Jan Jaap van Lier

Hepatology· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
Dirk Schürmann, Gerd Fätkenheuer, Jacques Reynes, Christian Michelet, Francois Raffi, Jan van Lier

AIDS· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.
Richard S Geary, JoAnn D Bradley, Tanya Watanabe, Younggil Kwon, Mark Wedel, Jan J van Lier

Clin Pharmacokinet· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Elevated serum ferritin and hemochromatosis in general practice].
Gunnar Mouland, Bjørn Bratland, Magn-Bjørn Hornnes, Hans Petter Asser, Jan Lier

Tidsskr Nor Laegeforen· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of effect of amisulpride on the pharmacokinetics and safety of lithium.
Muriel Canal, Eric Legangneux, Jan Jaap van Lier, Andre Antonius van Vliet, Catherine Coulouvrat

Int J Neuropsychopharmacol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Graft-versus-host disease-like eruption preceding a nodal CD30+ lymphoma.
Johan Toonstra, Jan G Lier, Peter M Steijlen, Peter C M van de Kerkhof

Eur J Dermatol· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis